Actively Recruiting
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-01-07
28
Participants Needed
1
Research Sites
214 weeks
Total Duration
On this page
Sponsors
A
Abramson Cancer Center at Penn Medicine
Lead Sponsor
G
Genentech, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.
CONDITIONS
Official Title
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older with advanced non-squamous non-small cell lung cancer (Stage IV or recurrent after curative therapy)
- Prior treatment with at least one line of therapy
- Prior exposure to a checkpoint inhibitor in the therapy immediately before this trial
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2
You will not qualify if you...
- Presence of a driver mutation treatable with targeted therapy
- Grade 3 or higher toxicity from prior immunotherapy according to CTCAE v5
- Other active invasive cancers requiring treatment
- Untreated or progressing brain metastases
- History or evidence of leptomeningeal disease
- Uncontrolled tumor-related pain
- History of autoimmune disease or idiopathic pulmonary fibrosis (IPF)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
M
Melissa Volpe, BA
CONTACT
M
Melina Marmarelis, MD, MSCE
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here